Thalix
Intended to relieve multiple myeloma proliferation to support clinical remission and target neoplastic pathways.
- Category
- Oncology Support
- Active ingredient
- Thalidomide
- Route
- Oral use
- Form
- Capsule
- Strengths
- 50mg
Prescription and consultation requirements for Thalix vary by destination and are determined by the fulfilment partner.
Thalix details
- Conditions
- Multiple Myeloma · Erythema Nodosum Leprosum
- Alternative names
- thalidomide
- Therapeutic class
- Immunomodulatory Agent
- Pharmacological class
- Antineoplastic
- Contraindications
- pregnancy; hypersensitivity to thalidomide
- Minor side effects
- constipation; fatigue; headache
- Moderate side effects
- somnolence; peripheral neuropathy; dry skin
- Dosage forms
- Capsule
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Celgene
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Dexamethasone; Anticoagulants
- Age restrictions
- Approved for adults.
Serious side effects
phocomelia, requires immediate medical attention; deep vein thrombosis, requires immediate medical attention; severe peripheral neuropathy, requires immediate medical attention
Patient summary
intended to relieve multiple myeloma proliferation to support clinical remission and target neoplastic pathways.
Mechanism of action
Inhibits basic TNF-alpha synthesis, blocks tumour cell division, and prevents angiogenesis within neoplastic structures.
Pregnancy and breastfeeding
TGA Category X: Highly teratogenic. Avoid any exposure. Use strict contraception protocols. Breastfeeding: Contraindicated.